[3] That proves its possible in the lab with advanced tech, but its a far cry from the supplement-style GLP-1 patches sold online today, which dont contain semaglutide and have never been through clinical trials
Indian companies are also developing a biosimilar for semaglutide where it seems that the patent will not be respected after 2026
While these results are highly encouraging, Retatrutide is undergoing further trials, such as TRIUMPH-2 and TRIUMPH-3
Retatrutide dose schedule compared to tirzepatide and semaglutide Understanding how the retatrutide dose schedule differs from the two currently available GLP-1 agonists helps put the titration timeline in perspective
MD snapshots taken at frame 4000 (200 ns) of Ex4-L-Ala ( a ), Ex4 ( c ) and Ex4-D-Ala ( e ) bound to the GLP-1R from the selected simulated rebinding replicates
Updated June 30, 2026 with latest coverage info Get your free 30-day heart health guide Evidence-based steps to optimize your heart health.